Evaluation of Tumour-Associated Antigen (TAA) Miniarray in Immunodiagnosis of Colon Cancer
Evaluation of Tumour-Associated Antigen (TAA) Miniarray in Immunodiagnosis of Colon Cancer
复制标题
肿瘤相关抗原（TAA）微阵列在结肠癌免疫诊断中的评价
DOI：
10.1111/j.1365-3083.2008.02195.x
复制
发表时间：
2009-01-01
影响因子：
3.7
通讯作者：
Zhang, J.
中科院分区：
文献类型：
--
作者：
Liu, W.;Wang, P.;Zhang, J.
以前的研究表明，癌症血清含有抗体，这些抗体与一组独特的自体细胞抗原发生反应，称为肿瘤相关抗原(TAAs)。这项研究确定了多个TAA的微型阵列是否会增强抗体检测，并成为结肠癌检测和诊断的有用方法。多个TAA的微阵列由Imp1、p62、Koc、p53和c-myc 5个TAA全长重组蛋白组成。应用酶联免疫吸附试验(EL ISA)检测了46例结肠癌患者和58例正常人血清中这5种TAA的抗体。结肠癌患者对任何个体TAA的抗体频率在15.2%至23.9%之间变化。随着五种抗原的相继加入，结肠癌抗体阳性反应逐步增加，敏感性为60.9%，特异性为89.7%。阳性似然比为5.91，阴性似然比为0.43，提示五种TAA平行检测具有较高的临床诊断价值。阳性预测值和阴性预测值分别为82.4%和74.3%，说明五项TAA平行检测大大提高了诊断的准确性。符合率和Kappa值分别为76.9%和0.52，说明该方法的观测值与实际值有中等范围的一致性。这项研究的数据进一步支持了我们之前的假设，即通过使用几个TAA作为靶抗原的微型阵列可以增强对某些类型癌症的自身抗体的检测。在19例癌胚抗原(CEA)阴性的结肠癌血清中，11例(57.9%)抗TAA抗体阳性。CEA和抗-TAA联合作为结肠癌标志物时，诊断敏感性由60.9%提高到82.6%。使用一组适当选择的TAA的定制抗原微阵列可以增强结肠癌免疫诊断中的自身抗体检测。抗TAA和CEA是两个独立的标志物，联合使用可显著提高结肠癌检测的敏感性。
Previous studies demonstrated that cancer sera contain antibodies, which react with a unique group of autologous cellular antigens called tumour-associated antigens (TAAs). This study determines whether a mini-array of multiple TAAs would enhance antibody detection and be a useful approach in colon cancer detection and diagnosis. The mini-array of multiple TAAs was composed of five TAAs including Imp1, p62, Koc, p53 and c-myc full-length recombinant proteins. Enzyme-linked immunosorbent assay (ELISA) was used to detect antibodies against these five TAAs in 46 sera from patients with colon cancer and also 58 sera from normal individuals. Antibody frequency to any individual TAA in colon cancer was variable and ranged from 15.2% to 23.9%. With the successive addition of TAAs to a final total of five antigens, there was a stepwise increase of positive antibody reactions reaching a sensitivity of 60.9% and a specificity of 89.7% in colon cancer. Positive and negative likelihood ratio was 5.91 and 0.43 respectively, which showed that the clinical diagnostic value of parallel assay of five TAAs was high. Positive and negative predictive values were respectively 82.4% and 74.3% indicating that parallel assay of five TAAs raised the diagnostic precision greatly. Agreement rate and Kappa value were 76.9% and 0.52 respectively, which indicated that the observed value of this assay had middle range coincidence with actual value. The data from this study further support our previous hypothesis that detection of autoantibodies for diagnosis of certain type of cancer can be enhanced by using a mini-array of several TAAs as target antigens. In 19 colon cancer sera with carcinoembryonic antigen (CEA) negative, 11 (57.9%) were found to have anti-TAA antibodies. When CEA and anti-TAAs were used together as markers in colon cancer detection, the diagnostic sensitivity could be raised from 60.9% to 82.6%. A customized antigen mini-array using a panel of appropriately selected TAAs can enhance autoantibody detection in immunodiagnosis of colon cancer. Anti-TAA and CEA were independent markers and the simultaneous use of these two markers significantly raised the sensitivity of colon cancer detection.